Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 21 | 2021 | 388 | 2.750 |
Why?
|
| Homosexuality, Male | 7 | 2021 | 83 | 1.340 |
Why?
|
| Anti-HIV Agents | 6 | 2017 | 54 | 1.240 |
Why?
|
| Bisexuality | 3 | 2021 | 17 | 0.850 |
Why?
|
| Continuity of Patient Care | 2 | 2019 | 70 | 0.650 |
Why?
|
| Viral Load | 6 | 2018 | 70 | 0.610 |
Why?
|
| North Carolina | 14 | 2021 | 1520 | 0.590 |
Why?
|
| Rural Population | 4 | 2015 | 274 | 0.590 |
Why?
|
| Community-Based Participatory Research | 5 | 2021 | 113 | 0.580 |
Why?
|
| HIV-1 | 3 | 2015 | 46 | 0.540 |
Why?
|
| Internet | 4 | 2011 | 203 | 0.480 |
Why?
|
| Antiretroviral Therapy, Highly Active | 5 | 2017 | 29 | 0.460 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2012 | 37 | 0.420 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2011 | 1 | 0.410 |
Why?
|
| Nitriles | 1 | 2011 | 23 | 0.400 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2011 | 17 | 0.400 |
Why?
|
| Adult | 22 | 2021 | 9467 | 0.390 |
Why?
|
| Pyrimidines | 1 | 2011 | 65 | 0.380 |
Why?
|
| Qualitative Research | 4 | 2021 | 159 | 0.370 |
Why?
|
| Appointments and Schedules | 3 | 2019 | 21 | 0.350 |
Why?
|
| Health Education | 2 | 2010 | 157 | 0.350 |
Why?
|
| HIV | 2 | 2019 | 24 | 0.340 |
Why?
|
| Humans | 29 | 2021 | 32297 | 0.310 |
Why?
|
| Male | 25 | 2021 | 19488 | 0.300 |
Why?
|
| Anti-Retroviral Agents | 1 | 2007 | 21 | 0.300 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2017 | 32 | 0.300 |
Why?
|
| Referral and Consultation | 2 | 2019 | 140 | 0.290 |
Why?
|
| Hispanic Americans | 4 | 2021 | 949 | 0.290 |
Why?
|
| Young Adult | 11 | 2019 | 2626 | 0.280 |
Why?
|
| Ambulatory Care Facilities | 3 | 2019 | 83 | 0.210 |
Why?
|
| HIV Seropositivity | 2 | 2014 | 14 | 0.210 |
Why?
|
| Emigrants and Immigrants | 4 | 2012 | 250 | 0.200 |
Why?
|
| Interviews as Topic | 2 | 2021 | 263 | 0.200 |
Why?
|
| Health Services Accessibility | 2 | 2015 | 242 | 0.200 |
Why?
|
| Middle Aged | 16 | 2019 | 11949 | 0.190 |
Why?
|
| Female | 17 | 2019 | 20126 | 0.190 |
Why?
|
| Patient Dropouts | 2 | 2019 | 28 | 0.180 |
Why?
|
| Medication Adherence | 2 | 2012 | 161 | 0.170 |
Why?
|
| Drug Therapy, Combination | 3 | 2015 | 301 | 0.170 |
Why?
|
| African Continental Ancestry Group | 1 | 2021 | 364 | 0.170 |
Why?
|
| Directive Counseling | 1 | 2019 | 18 | 0.170 |
Why?
|
| Case Management | 1 | 2018 | 5 | 0.160 |
Why?
|
| Ambulatory Care | 1 | 2019 | 108 | 0.150 |
Why?
|
| Strongyloidiasis | 1 | 2017 | 3 | 0.150 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 18 | 0.150 |
Why?
|
| Treatment Outcome | 4 | 2015 | 3358 | 0.150 |
Why?
|
| Smoking Cessation | 1 | 2019 | 195 | 0.150 |
Why?
|
| Drug Administration Schedule | 3 | 2017 | 279 | 0.150 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 353 | 0.150 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2017 | 9 | 0.150 |
Why?
|
| Bacterial Infections | 1 | 2017 | 52 | 0.140 |
Why?
|
| European Continental Ancestry Group | 1 | 2021 | 1180 | 0.140 |
Why?
|
| Smoking | 1 | 2019 | 493 | 0.130 |
Why?
|
| Social Support | 2 | 2019 | 180 | 0.130 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2015 | 7 | 0.130 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2015 | 2 | 0.130 |
Why?
|
| Pyridazines | 1 | 2015 | 7 | 0.130 |
Why?
|
| Longitudinal Studies | 2 | 2015 | 786 | 0.130 |
Why?
|
| Lipid Metabolism | 1 | 2015 | 103 | 0.120 |
Why?
|
| Southeastern United States | 5 | 2014 | 81 | 0.120 |
Why?
|
| Risk-Taking | 3 | 2011 | 97 | 0.120 |
Why?
|
| Bone Density | 1 | 2015 | 186 | 0.120 |
Why?
|
| Pruritus | 1 | 2014 | 64 | 0.110 |
Why?
|
| Sexual Behavior | 2 | 2012 | 106 | 0.110 |
Why?
|
| Adolescent | 7 | 2019 | 3571 | 0.110 |
Why?
|
| Diffusion of Innovation | 1 | 2012 | 34 | 0.110 |
Why?
|
| Cooperative Behavior | 1 | 2012 | 80 | 0.100 |
Why?
|
| Mexican Americans | 1 | 2012 | 60 | 0.100 |
Why?
|
| Commerce | 1 | 2011 | 43 | 0.100 |
Why?
|
| Pharmaceutical Preparations | 1 | 2011 | 37 | 0.100 |
Why?
|
| Safe Sex | 2 | 2009 | 14 | 0.100 |
Why?
|
| AIDS Serodiagnosis | 1 | 2011 | 4 | 0.100 |
Why?
|
| Aged | 5 | 2014 | 10398 | 0.100 |
Why?
|
| Intention | 1 | 2011 | 28 | 0.090 |
Why?
|
| Sexual Partners | 2 | 2009 | 35 | 0.090 |
Why?
|
| Cohort Studies | 1 | 2015 | 1832 | 0.090 |
Why?
|
| Peer Group | 2 | 2010 | 44 | 0.090 |
Why?
|
| Community-Institutional Relations | 2 | 2007 | 18 | 0.090 |
Why?
|
| Time Factors | 2 | 2015 | 2181 | 0.090 |
Why?
|
| RNA, Viral | 1 | 2009 | 52 | 0.090 |
Why?
|
| Focus Groups | 2 | 2007 | 111 | 0.090 |
Why?
|
| Heterosexuality | 1 | 2009 | 13 | 0.080 |
Why?
|
| Ritonavir | 1 | 2007 | 3 | 0.080 |
Why?
|
| Pyrimidinones | 1 | 2007 | 4 | 0.080 |
Why?
|
| Quality of Life | 1 | 2014 | 915 | 0.080 |
Why?
|
| African Americans | 1 | 2015 | 1443 | 0.080 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2007 | 4 | 0.080 |
Why?
|
| Condoms | 1 | 2007 | 35 | 0.080 |
Why?
|
| Methamphetamine | 1 | 2007 | 17 | 0.070 |
Why?
|
| Drug Resistance, Viral | 3 | 2015 | 10 | 0.070 |
Why?
|
| Morbidity | 1 | 2007 | 98 | 0.070 |
Why?
|
| Health Behavior | 1 | 2009 | 229 | 0.070 |
Why?
|
| Unsafe Sex | 1 | 2007 | 24 | 0.070 |
Why?
|
| Poverty | 1 | 2007 | 111 | 0.070 |
Why?
|
| Emigration and Immigration | 1 | 2006 | 32 | 0.070 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 2296 | 0.070 |
Why?
|
| Community Health Services | 1 | 2006 | 55 | 0.070 |
Why?
|
| Patient Compliance | 1 | 2007 | 227 | 0.070 |
Why?
|
| Attitude to Health | 1 | 2007 | 167 | 0.070 |
Why?
|
| Survival Rate | 1 | 2007 | 894 | 0.060 |
Why?
|
| Age Factors | 1 | 2007 | 1204 | 0.060 |
Why?
|
| Regression Analysis | 2 | 2017 | 296 | 0.050 |
Why?
|
| Counseling | 1 | 2019 | 99 | 0.040 |
Why?
|
| Substance-Related Disorders | 2 | 2012 | 124 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2007 | 4050 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2011 | 536 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2019 | 186 | 0.040 |
Why?
|
| Telephone | 1 | 2018 | 59 | 0.040 |
Why?
|
| Strongyloides stercoralis | 1 | 2017 | 3 | 0.040 |
Why?
|
| Piperacillin | 1 | 2017 | 5 | 0.040 |
Why?
|
| Penicillanic Acid | 1 | 2017 | 5 | 0.040 |
Why?
|
| Antiparasitic Agents | 1 | 2017 | 6 | 0.040 |
Why?
|
| Ivermectin | 1 | 2017 | 9 | 0.040 |
Why?
|
| Klebsiella pneumoniae | 1 | 2017 | 9 | 0.040 |
Why?
|
| Patient Participation | 1 | 2018 | 81 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2017 | 86 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 51 | 0.040 |
Why?
|
| Bacteremia | 1 | 2017 | 58 | 0.040 |
Why?
|
| Tuberculosis | 1 | 2017 | 15 | 0.040 |
Why?
|
| Australia | 1 | 2017 | 72 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2014 | 1447 | 0.040 |
Why?
|
| Pneumonia, Bacterial | 1 | 2017 | 32 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2014 | 1522 | 0.030 |
Why?
|
| Mass Screening | 1 | 2019 | 263 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2007 | 696 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2015 | 171 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 309 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 759 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2014 | 133 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2014 | 201 | 0.030 |
Why?
|
| Age Distribution | 1 | 2014 | 210 | 0.030 |
Why?
|
| Psychological Theory | 1 | 2012 | 6 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2014 | 406 | 0.030 |
Why?
|
| Reproductive Health Services | 1 | 2012 | 5 | 0.030 |
Why?
|
| Consumer Health Information | 1 | 2011 | 12 | 0.030 |
Why?
|
| Cultural Competency | 1 | 2011 | 19 | 0.020 |
Why?
|
| Risk Factors | 2 | 2012 | 3876 | 0.020 |
Why?
|
| Motivation | 1 | 2012 | 114 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 986 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 926 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2012 | 422 | 0.020 |
Why?
|
| Logistic Models | 1 | 2012 | 788 | 0.020 |
Why?
|
| United States | 1 | 2019 | 3983 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2010 | 124 | 0.020 |
Why?
|
| Random Allocation | 1 | 2009 | 220 | 0.020 |
Why?
|
| HIV Protease Inhibitors | 1 | 2007 | 1 | 0.020 |
Why?
|
| Genotype | 1 | 2009 | 742 | 0.020 |
Why?
|
| Stereotyping | 1 | 2007 | 9 | 0.020 |
Why?
|
| Videotape Recording | 1 | 2007 | 13 | 0.020 |
Why?
|
| Narration | 1 | 2007 | 18 | 0.020 |
Why?
|
| Prejudice | 1 | 2007 | 50 | 0.020 |
Why?
|
| Students | 1 | 2009 | 175 | 0.020 |
Why?
|
| Spirituality | 1 | 2007 | 34 | 0.020 |
Why?
|
| Mutation | 1 | 2009 | 503 | 0.020 |
Why?
|
| Data Collection | 1 | 2007 | 185 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2007 | 124 | 0.020 |
Why?
|
| Animals | 1 | 2017 | 7694 | 0.020 |
Why?
|
| Health Promotion | 1 | 2007 | 242 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2006 | 190 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2009 | 3514 | 0.010 |
Why?
|